Quick Take
Peloton Therapeutics (PLTX) has filed to raise gross proceeds of $115 million from a U.S. IPO, according to an S-1 registration statement.
The firm is developing small molecule therapeutics for the treatment of cancer and other debilitating diseases.
PLTX has earned positive Phase 1/2 trial results for its lead candidate with a high clinical benefit rate.
Company & Technology
Dallas, Texas-based Peloton was founded in 2010 to develop therapeutics for the treatment of cancer with an initial focus on the Hypoxia-inducible factor-2? [HIF-2?] transcription factor, which management claims was previously